Retatrutide 2mg (4 PENS)

BUY Retatrutide 2mg

Retatrutide is an investigational, once-weekly injectable peptide developed by Eli Lilly for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). The 2mg dose, administered via subcutaneous injection, is the starting dose in clinical trials, designed to minimize side effects during initiation. Not yet FDA-approved, it’s available only through phase 3 TRIUMPH trials (ongoing until 2026).

retatrutide vs tirzepatide

Mechanisms of Action
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and slows gastric emptying, GIP enhances insulin sensitivity and fat metabolism, and glucagon boosts energy expenditure by promoting fat burning. With a ~6-day half-life, it provides sustained effects. Phase 2 trials at 2mg showed ~8.7% weight loss and 1.4% HbA1c reduction over 48 weeks, setting the stage for higher doses.

retatrutide cost

Weight Loss: Achieves ~8–10% body weight loss (15–20 lbs) at 2mg with diet and exercise.

Blood Sugar Control: Lowers HbA1c by ~1.4% in type 2 diabetes patients.

Liver Health: Reduces liver fat, supporting MASLD treatment (data from higher doses).

Cardiometabolic Health: Improves blood pressure and lipid profiles (triglycerides, LDL).
Early appetite suppression and metabolic benefits are noticeable within 4–8 weeks.

retatrutide dose​

Dosage and Administration
Administer 2mg weekly for 4 weeks as the starting dose, injected into the abdomen, thigh, or upper arm, rotating sites. Take any time of day, with or without food. Escalate to 4mg or higher after 4 weeks, as tolerated, per trial protocols. Store vials refrigerated (36–46°F). If a dose is missed, inject within 4 days or skip until the next week.

retatrutide side effects

Common side effects include mild nausea, diarrhea, and constipation (10–20%), most prominent during early dosing. Serious risks, though rare, include transient heart rate increases and pancreatitis. Not suitable for those with thyroid cancer history or severe liver/renal impairment. Monitor for severe abdominal pain or allergic reactions. Long-term data is pending.

retatrutide starting dose​

Legal Status
Not FDA-approved; available only in clinical trials. Banned by WADA. Obtain through research protocols or select compounding pharmacies.